L1CAM expression in endometrial carcinomas: an ENITEC collaboration study

[1]  C. Ouyang,et al.  L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA). , 2016, Gynecologic oncology.

[2]  P. Altevogt,et al.  L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma , 2016, Pathology & Oncology Research.

[3]  H. Mackay,et al.  Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer , 2016, Modern Pathology.

[4]  T. Bosse,et al.  L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. , 2014, European journal of cancer.

[5]  P. Altevogt,et al.  A Standardized Staining Protocol for L1CAM on Formalin-Fixed, Paraffin-Embedded Tissues Using Automated Platforms , 2014, The International journal of biological markers.

[6]  Z. Ye,et al.  L1 and epithelial cell adhesion molecules associated with gastric cancer progression and prognosis in examination of specimens from 601 patients , 2013, Journal of experimental & clinical cancer research : CR.

[7]  P. Altevogt,et al.  L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. , 2013, Journal of the National Cancer Institute.

[8]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[9]  X. Matías-Guiu,et al.  Molecular pathology of endometrial carcinoma , 2013, Histopathology.

[10]  P. Altevogt,et al.  EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation. , 2012, Carcinogenesis.

[11]  Marta García,et al.  The EMT signaling pathways in endometrial carcinoma , 2012, Clinical and Translational Oncology.

[12]  P. Altevogt,et al.  Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Frotscher,et al.  Role of L1CAM for axon sprouting and branching , 2012, Cell and Tissue Research.

[14]  G. Kristiansen,et al.  L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer , 2011, Molecular Cancer.

[15]  H. Kijima,et al.  L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma , 2011, Journal of surgical oncology.

[16]  A. Ben-Ze'ev,et al.  L1-Mediated Colon Cancer Cell Metastasis Does Not Require Changes in EMT and Cancer Stem Cell Markers , 2010, Molecular Cancer Research.

[17]  A. Ben-Ze'ev,et al.  Nuclear factor-κB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells , 2010, Journal of Cell Science.

[18]  P. Altevogt,et al.  Up‐regulation of L1CAM is linked to loss of hormone receptors and E‐cadherin in aggressive subtypes of endometrial carcinomas , 2010, The Journal of pathology.

[19]  F. Feuerhake,et al.  Expression and prognostic value of L1-CAM in breast cancer. , 2009, Oncology reports.

[20]  E. Fischer,et al.  The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. , 2009, The international journal of biochemistry & cell biology.

[21]  P. Altevogt,et al.  Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer. , 2009, Cancer research.

[22]  P. Altevogt,et al.  The RGD integrin binding site in human L1-CAM is important for nuclear signaling. , 2008, Experimental cell research.

[23]  P. Altevogt,et al.  The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies , 2007, Oncogene.

[24]  P. Altevogt,et al.  Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells , 2007, Oncogene.

[25]  P. Altevogt,et al.  L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. , 2007, Gynecologic oncology.

[26]  P. Altevogt,et al.  Copper-67 Radioimmunotherapy and Growth Inhibition by Anti–L1-Cell Adhesion Molecule Monoclonal Antibodies in a Therapy Model of Ovarian Cancer Metastasis , 2007, Clinical Cancer Research.

[27]  Y. Chae,et al.  L1 Expression as a Marker for Poor Prognosis, Tumor Progression, and Short Survival in Patients with Colorectal Cancer , 2007, Annals of Surgical Oncology.

[28]  I. Roninson,et al.  Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. , 2006, Cancer research.

[29]  L. Akslen,et al.  Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. , 2006, American journal of obstetrics and gynecology.

[30]  Y. Allory,et al.  The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  Andreas Sommer,et al.  NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression , 2004 .

[32]  S. Lax.  Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification , 2004, Virchows Archiv.

[33]  P. Altevogt,et al.  L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas , 2003, The Lancet.

[34]  P. Altevogt,et al.  Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins , 2001, The Journal of cell biology.

[35]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[36]  H. Pehamberger,et al.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. , 2004, The Journal of clinical investigation.

[37]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[38]  C. Bankhead,et al.  [Cancer of the corpus uteri]. , 1979, Fel'dsher i akusherka.